- Home
- NCTY vs IXHL Comparison
NCTY vs IXHL Comparison
Compare NCTY & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCTY | IXHL |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.8M | 97.6M |
| IPO Year | 2004 | 2024 |
Fundamental Metrics
Financial Performance| Metric | NCTY | IXHL |
|---|---|---|
| Price | $6.12 | $3.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.2K | ★ 4.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $0.11 |
| 52 Week High | $15.98 | $6.39 |
Technical Indicators
Market Signals| Indicator | NCTY | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 49.61 | 56.41 |
| Support Level | $5.02 | $0.31 |
| Resistance Level | $7.37 | $5.17 |
| Average True Range (ATR) | 0.58 | 0.51 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 43.35 | 49.82 |
Price Performance
Historical ComparisonAbout NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.